Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245335 | 0.98 | TDP1 (0.50) | TDP1CYP2D6CYP2C19LMNAMEN1 | |
| SCHEMBL27395096 | 0.82 | CYP2A13 (0.46) | TDP1CYP2D6CYP2C19MEN1KMT2A | |
| SCHEMBL4558224 | 0.82 | KMT2A (0.48) | TDP1CYP2D6CYP2C19LMNAMEN1 | |
| SCHEMBL11548078 | 0.78 | CA12 (0.52) | MEN1KMT2ATSHRALDH1A1POLB | |
| SCHEMBL29995599 | 0.78 | CA12 (0.52) | MEN1KMT2ATSHRALDH1A1POLB | |
| SCHEMBL16825239 | 0.76 | KDM4E (0.43) | LMNAMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL23850504 | 0.75 | ALDH1A1 (0.47) | TDP1CYP2D6CYP2C19LMNAMEN1 | |
| SCHEMBL3174770 | 0.75 | TSHR (0.50) | CYP2D6CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL2092995 | 0.75 | TERT (0.41) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL2092991 | 0.73 | ALDH1A1 (0.40) | MEN1KMT2ATSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | TDP1 4420/4885CYP2D6 2280/4885CYP2C19 1818/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | TDP1 4420/4885CYP2D6 2280/4885CYP2C19 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.